PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportshepatocellular carcinoma
MeSH D006528 - hepatocellular carcinoma
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D008113:Liver neoplasms
0 Companies
0 Drugs
Success rate
D000230:Adenocarcinoma
24 Companies
3 Drugs
$
Success rate
D006528: 
Hepatocellular carcinoma
16 Companies
12 Drugs
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaSorafenib Sorafenib  2020-11-12   
MylanSorafenib Sorafenib  2020-09-10   
RocheRibavirin, Peginterferon alfa-2a Pegasys Copegus  2004-06-04   
Interferon alfa-2a Roferon-A  1986-06-04   
Atezolizumab Tecentriq  2017-09-20 $4,406.336 M Q4/22-Q3/23 
AstraZenecaTremelimumab Imjudo  2022-10-21 $13 M Y2024 
Tremelimumab Tremelimumab AstraZeneca  2023-02-20   
Merck & CoInterferon alfa-2b Intron A  1986-06-04   
Interferon alfa-2b IntronA  2000-03-09   
Peginterferon alfa-2b PegIntron  2001-01-19   
Ribavirin, Peginterferon alfa-2b PegIntron/ Rebetol Combo Pack  2008-06-13   
Interferon alfa-2b Viraferon  2000-03-09   
Peginterferon alfa-2b ViraferonPeg  2000-05-28   
BayerSorafenib Nexavar 2023-02-11 2005-12-20   
Regorafenib Stivarga 2022-06-28 2012-09-27   
Dr Reddys LaboratoriesSorafenib Sorafenib  2022-06-07   
Accord HealthcareSorafenib Sorafenib Accord  2022-11-09   
Horizon Therapeutics PublicInterferon gamma-1b Actimmune  1999-02-25 $122.816 M Q3/22-Q2/23 
Pharma&Peginterferon alfa-2a Pegasys  2002-10-16   
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
74%
51/69
Phase 2
25%
25/100
Phase 3
30%
11/37
Approved: 8Overall Success rate: 5%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
PIDILIZUMAB
Roche
Ribavirin,
Atezolizumab,
Peginterferon alfa-2a,
Interferon alfa-2a,
Vitamin k,
Tiragolumab,
Enoblituzumab,
Onartuzumab,
Maxacalcitol,
Aspartame,
Bevifimod,
CODRITUZUMAB,
Nepidermin,
Telbermin,
Retinol,
Fendrix,
RO7247669,
Becavizumab,
RO5323441,
Ro7070179,
Arm1,
Arm2,
Demand,
Ro7119929
AstraZeneca
Tremelimumab,
Gilvetmab,
Aglatimagene besadenovec,
Lornoxicam,
Sodium chloride,
Bevifimod,
DANVATIRSEN,
Nepidermin,
Telbermin,
Edetic acid,
Azd2936,
Fendrix,
AZD8055,
Arm1,
Arm2,
AZD1480,
Krn951,
Therasphere
Merck & Co
Ribavirin,
Interferon alfa-2b,
Peginterferon alfa-2b,
E-7386,
Gilvetmab,
Epacadostat,
Aglatimagene besadenovec,
Bavituximab,
Maxacalcitol,
Doconexent,
Lornoxicam,
Sodium chloride,
Albinterferon alfa-2b,
Aspartame,
Bevifimod,
Nepidermin,
Quavonlimab,
Recombivax,
Caelyx,
Fendrix,
Doxorubin,
Mk3475,
Arm1,
Hydroxydaunomycin,
Arm2,
Gb1275,
Q702,
E7389,
Therasphere
Bayer
Regorafenib,
Sorafenib,
Cilmostim,
Gilvetmab,
Enoblituzumab,
Gadoxetic acid,
Molgramostim,
Sodium chloride,
Bevifimod,
Nepidermin,
REFAMETINIB,
Telbermin,
Edetic acid,
Corticoids,
Caelyx,
Fendrix,
Doxorubin,
Mk3475,
Arm1,
Hydroxydaunomycin,
Demand,
Therasphere,
Primovist
Yabao Pharmaceutical
Sorafenib
Ipsen
Cabozantinib,
Tasquinimod
Genentech
Atezolizumab,
Hyaluronidase,
Hyaluronidase (human recombinant),
Linifanib,
Aspartame,
Bevifimod
1
2
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use